Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

被引：0
|
作者：
Le, H. [1 ]
Coulter, J. [2 ]
Cappelleri, J. C. [2 ]
Lu, H. [3 ]
Quaife, M. [3 ]
Meginnis, K. [3 ]
Fernandez, G. [3 ]
Culver, K. [4 ]
Vaghela, S. [2 ]
Rifi, N. [2 ]
Stinchcombe, T. [5 ]
机构：
[1] Pfizer Inc, Fairfax, VA USA
[2] Pfizer Inc, New York, NY USA
[3] Evidera, Cambridge, England
[4] ALK Posit, Atlanta, GA USA
[5] Duke Hlth, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Preference; ALK; TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.05
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [21] THE ROLE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Mok, Tony
    ANNALS OF ONCOLOGY, 2010, 21 : 5 - 5
  • [22] CLINICAL MODES OF EGFR TYROSINE KINASE INHIBITOR FAILURE AND SUBSEQUENT MANAGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Chen, H.
    Yang, J.
    Yan, H.
    Zhang, X.
    Wu, Z.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 437 - 437
  • [23] TUMOR BURDEN AND TYROSINE KINASE INHIBITORS (TKI) BENEFIT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR SENSITIZING MUTATIONS (EGFRM) AND ALK REARRANGEMENT (ALK plus )
    Leduc, C.
    Moussa, N.
    Faivre, L.
    Biondani, P.
    Pignon, J.
    Caramella, C.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S37 - S37
  • [24] Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
    Yang, Jin-Ji
    Chen, Hua-Jun
    Yan, Hong-Hong
    Zhang, Xu-Chao
    Zhou, Qing
    Su, Jian
    Wang, Zhen
    Xu, Chong-Rui
    Huang, Yi-Sheng
    Wang, Bin-Chao
    Yang, Xue-Ning
    Zhong, Wen-Zhao
    Nie, Qiang
    Liao, Ri-Qiang
    Jiang, Ben-Yuan
    Dong, Song
    Wu, Yi-Long
    LUNG CANCER, 2013, 79 (01) : 33 - 39
  • [25] Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy
    Ning, Ye
    Bao, Minwei
    Yan, Xiaoxia
    Xie, Dong
    Jiang, Gening
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (20)
  • [26] Innovative treatments for advanced non-small cell lung cancer
    Tester, W
    Mora, J
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (06) : 1021 - 1032
  • [27] Antiangiogenic treatments of advanced non-small cell lung cancer
    Christian Manegold
    Targeted Oncology, 2008, 3 : 187 - 196
  • [28] Antiangiogenic treatments of advanced non-small cell lung cancer
    Manegold, Christian
    TARGETED ONCOLOGY, 2008, 3 (03) : 187 - 196
  • [29] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
  • [30] AN INCREMENTAL EFFECTIVENESS ANALYSIS OF LORLATINIB FOR THE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER THAT HAS PROGRESSED AFTER ANOTHER ALK TYROSINE KINASE INHIBITOR IN PORTUGAL
    Guerreiro, R.
    Paquete, A. T.
    Iadeluca, L.
    Almond, C.
    Albuquerque de Almeida, F.
    Ines, M.
    Costa, J.
    Borges, M.
    Silva Miguel, L.
    VALUE IN HEALTH, 2020, 23 : S433 - S433
12345